PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
52 hedge funds and large institutions have $245M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 15 increasing their positions, 1 reducing their positions, and 3 closing their positions.
1,400% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 1
1,100% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 3
272% more capital invested
Capital invested by funds: $65.8M → $245M (+$179M)
174% more funds holding
Funds holding: 19 → 52 (+33)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$81.4M |
| 2 |
DM
Deerfield Management
New York
|
+$10.4M |
| 3 |
BlackRock
New York
|
+$10.4M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$9.28M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.16M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$407K |
| 3 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$217K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$13.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GT
51
Glenmede Trust
Philadelphia,
Pennsylvania
| $65 | +$61.3K | +5,000 | New |
|
|
52
Millennium Management
New York
| – | -$1.16M | -121,979 | Closed |
|
|
53
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$407K | -42,845 | Closed |
|
|
TEE
54
Tibra Equities Europe
London,
United Kingdom
| – | -$217K | -22,778 | Closed |
|
55
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$86 | +7 | New |
|
PHAS Hedge Fund Activity: Q2 2019 in Review
52 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q2 2019, worth a combined $245M — up 272% from $65.8M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new PHAS positions and 3 closed out — a net gain of 33 holders — while 15 added to existing stakes and 1 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $81.4M. The largest seller was Millennium Management, exiting entirely with an estimated $1.16M sold.
- 52 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q2 2019, up from 19 in Q1 2019.
- Funds reported $245M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q2 2019, up 272% quarter-over-quarter.
- 36 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q2 2019 and 3 closed out, a net change of +33 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q2 2019 was NEA Management Company, an estimated $81.4M added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q2 2019 was Millennium Management, an estimated $1.16M sold.
Based on aggregated 13F filings for Q2 2019.